Sanofi India (SIL) has received approval from board of directors to demerge its consumer healthcare business into a separate entity. The company's board has approved the Scheme of Arrangement between Sanofi India and its wholly-owned subsidiary Sanofi Consumer Healthcare India (SCHIL).
This decision will open new gates for the India business and employees in a value-driven move to accelerate growth for both the pharmaceuticals business (SIL) and consumer healthcare business (SCHIL) in India. This is a momentous opportunity as it will allow Sanofi to unlock and maximise its business potential in both pharmaceuticals and consumer healthcare, with the right assets, structure, and strategy.
Upon completion of the proposed demerger, Sanofi will continue to own 60.4 per cent stake in both entities and SIL shareholders will receive 1:1 SCHIL equity share of Rs 10 each, for each equity share owned.
Sanofi India is a global biopharmaceutical company focused on human health.
